Alpha memo: resveratrol exercise training cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename or refine the title so the anchor (resveratrol) and the contrast axis (tissue/species/endpoint) are both explicit and match the receipts.
2. Complete or cleanly truncate Receipt 2's numeric in the body; do not leave a half-sentence number dangling.
3. Soften the framing from 'evidence signal' to 'two-receipt cross-context contrast' or similar, since two heterogeneous receipts constitute a hypothesis, not a signal.
4. Tighten the falsifier section: explicitly state that no human trial has tested both endpoints within the same population, and that the moderator hypothesis is purely speculative pending such a trial.

Minor issues

• The title frames a 'cross-context evidence signal' but the memo only cites two receipts; calling this a 'signal' overstates a two-paper cross-tissue contrast and could be reframed as a 'hypothesis-generating contrast.'
• Receipt 2's numeric is truncated mid-sentence ('45 (truncated) change in MAP') in the memo body; this should either be completed from the source bundle (the bundle excerpt ends at the same truncation point) or explicitly flagged as unverifiable rather than reproduced as a dangling number.
• The title says 'exercise training cross-context' but never names resveratrol; for a memo anchor it would be cleaner to lead with the compound (e.g., 'resveratrol + high-intensity exercise: cross-tissue, cross-species contrast').

Reviewer note

The memo correctly identifies two genuinely contrasting receipts on the same anchor (resveratrol + high-intensity exercise): a 2023 mouse study showing attenuation of intestinal inflammation/ferroptosis via Nrf2/FTH1/GPX4, and a 2013 human RCT (Gliemann et al., n=27 aged men) showing blunting of training-induced MAP reduction. Both receipts are real, accurately cited, and the cross-tissue/cross-species tension is honestly stated. The caveats about species, dose, duration, and endpoint heterogeneity are specific and materially constrain any inference. The falsifier (a within-population RCT measuring both endpoints) is well-targeted. The main weaknesses are presentational: (1) title does not name the anchor compound; (2) the word 'signal' overstates what two heterogeneous receipts can support; (3) a truncated numeric is reproduced mid-sentence; (4) the abstract and body use slightly different wording for the same contrast. These are bounded fixable edits, not structural flaws. The memo does not make clinical, policy, or investment claims and appropriately limits itself to flagging a cross-context tension. Recommend revise with the listed edits.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis